⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68680 | 1.00 | — | — | |
| SCHEMBL30356501 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1494455 | 0.98 | ACACB (0.36) | — | |
| Hydrochloric Acid SCHEMBL1494453 | 0.98 | ACACB (0.36) | — | |
| SCHEMBL20123209 | 0.85 | PDCD1LG2 (0.37) | — | |
| SCHEMBL31098914 | 0.85 | — | — | |
| SCHEMBL68755 | 0.82 | ALOX15 (0.38) | — | |
| SCHEMBL20733126 | 0.80 | PDCD1LG2 (0.32) | — | |
| SCHEMBL272661 | 0.79 | CA2 (0.53) | — | |
| SCHEMBL84553 | 0.79 | CA2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| EP-4196228-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | Albert Einstein College of Medicine (US) | 2023-06-21 | — | — | EP | disclosed |
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230116233-A1 | Compounds And Compositions As Protein Kinase Inhibitors | ARRAY BIOPHARMA INC (US) | 2023-04-13 | — | — | US | disclosed |
| CN-114557977-A | Preparation method, preparation and purity analysis method of medicine for treating intestinal cancer | 北京康立生医药技术开发有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-114181197-B | Preparation method, preparation and purity analysis method of medicine for treating intestinal cancer | 北京康立生医药技术开发有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-114181197-A | Preparation method, preparation and purity analysis method of medicine for treating intestinal cancer | 北京康立生医药技术开发有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | disclosed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | disclosed |
| US-20130096149-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |